Abstract 375P
Background
To determined survival and prognostic factors for non-nasopharyngeal head and neck squamous cell carcinoma (HNSCC) patients treated with surgery followed by concurrent chemoradiotherapy (CCRT) or definitive CCRT (dCCRT), aiming to identify optimal chemotherapy doses.
Methods
This retrospective cohort study reviewed 277 non-NPC HNSCC patients treated with platinum-based CCRT at Rajavithi Hospital between January 1st, 2016 and April 30th, 2021. Clinical features, staging, treatment, and outcomes were collected and analyzed.
Results
Overall, 277 patients were diagnosed as HNSCC; median age: 55.9 years; male: 81.2%; ECOG 0-1: 98.9%. The clinical stage was I-III, IVa, and IVb in 23.8%, 53.4%, and 22.8%, respectively. Cisplatin was used in 39.0%, while carboplatin was used in 61.0%. 53.4% underwent surgery followed by CCRT while 46.6% underwent definitive CCRT. Patients treated with adjuvant CCRT led to significantly longer overall survival (OS) and disease-free survival (DFS) than definitive CCRT (HR: 0.54, p<0.001 for OS; HR: 0.61, p<0.001 for DFS). Higher stage and the presence of pathological risk factors were poor prognostic factors for OS in the adjuvant CCRT group, while higher stage and oral cavity and hypopharynx were associated with poorer OS in the definitive CCRT group. Among the interquartile range of cumulative doses (CDs), the study also found a statistically significant difference in OS and DFS for the dCCRT group with carboplatin at the 2nd Quartile compared to the others (6.75-8.58 AUC) (HR 0.38, 95%CI; 0.17-0.86, p=0.02 and HR 0.41, 95%CI; 0.18-0.91, p=0.03, respectively). There was no significant difference in OS/DFS between patients who received CDs of cisplatin of either less or more than 200 mg/m2 or carboplatin in adjuvant CCRT in all population.
Conclusions
This study showed comparable survival outcomes to historical data. Surgery followed by adjuvant CCRT remains the recommended approach. The CDs of cisplatin or carboplatin did not significantly impact outcomes. A trend towards improved survival with CDs within a specific range requires confirmation in further prospective studies.
Clinical trial identification
6518.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
270P - Germline BRCA1/2 pathogenic variants in Japanese patients with prostate cancer are predictive factors for androgen receptor-axis-targeted therapy or chemotherapy for castration-resistant prostate cancer
Presenter: Shigekatsu Maekawa
Session: Poster Display
Resources:
Abstract
271P - Prostate cancer with histone modifier UTX mutations can benefit from olaparib
Presenter: NOBUHITO MURAMOTO
Session: Poster Display
Resources:
Abstract
272P - Comparison between MRI-targeted and standard biopsy for prostate cancer detection: A systematic review and meta-analysis
Presenter: Andree Kurniawan
Session: Poster Display
Resources:
Abstract
273P - The diagnostic performance of cognitive MRI-targeted biopsy in biopsy-naïve patients undergoing systematic 14-region 18-core biopsy: Do the three areas affect the results?
Presenter: Yuka Toyama
Session: Poster Display
Resources:
Abstract
274P - Index tumor location influencing early biochemical recurrence after radical prostatectomy in patients with negative surgical margins
Presenter: Jun Akatsuka
Session: Poster Display
Resources:
Abstract
275P - Prognosis of metastatic castration-resistant prostate cancer in response to chemotherapy and PSMA expression in circulating tumor cells
Presenter: Naoya Nagaya
Session: Poster Display
Resources:
Abstract
276P - Prognostic significance of p53 mutation in metastatic hormone-sensitive prostate cancer
Presenter: Lakshmi Kamala
Session: Poster Display
Resources:
Abstract
277P - Vasohibin-1 expression as a biomarker of aggressive growth in prostate ductal adenocarcinoma
Presenter: Murad Salomov
Session: Poster Display
Resources:
Abstract
278P - Full-coverage radiotherapy for prostate cancer patients with oligometastases
Presenter: Bichun Xu
Session: Poster Display
Resources:
Abstract
279P - Hypofractionated radiotherapy protocol implementation and early outcomes for prostate cancer patients: A single institution retrospective review
Presenter: Thu Nguyen
Session: Poster Display
Resources:
Abstract